Pathstone Family Office’s T2 Biosystems, Inc TTOO Stock Holding History

Pathstone Family Office’s Portfolio TTOO Stock Details TTOO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-1	Closed	-$7K	–	1369
2020 Q3	$7K	Buy	+1	New	+$7.41K	﹤0.01%	640

Other funds holding TTOO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Pathstone Family Office's TTOO Position: Q4 2020 in Review

Pathstone Family Office sold out of T2 Biosystems, Inc (TTOO) in Q4 2020, closing a stake of 1 share — an estimated $7K sold.

Pathstone Family Office first reported a position in TTOO in Q3 2020 and held it in 1 quarter. The position peaked at $7K in Q3 2020. 62 funds tracked by Wall St. Rank hold TTOO as of Q4 2020.

Pathstone Family Office reported no remaining T2 Biosystems, Inc position as of Q4 2020 after selling out during the quarter.
Pathstone Family Office sold 1 T2 Biosystems, Inc share in Q4 2020, an estimated $7K.
Pathstone Family Office first reported a position in T2 Biosystems, Inc in Q3 2020 and held it in 1 quarter.
Pathstone Family Office's T2 Biosystems, Inc position peaked at $7K in Q3 2020.
62 funds tracked by Wall St. Rank held T2 Biosystems, Inc as of Q4 2020.

Based on Pathstone Family Office's 13F filing for Q4 2020, filed 16 Feb 2021.